Key Quantitative Figures

Standalone Financial Results (Q1 FY27)

  • Revenue from Operations: ₹10.86 lacs
  • Total Income: ₹10.86 lacs
  • Total Expenses: ₹69.82 lacs
  • Loss Before Tax: ₹(58.96) lacs
  • Tax Expense: ₹0.00 lacs
  • Net Loss for the Period: ₹(58.96) lacs
  • Basic & Diluted EPS: ₹(0.47)
  • Paid-up Equity Share Capital: ₹1247.00 lacs

Consolidated Financial Results (Q1 FY27)

  • Revenue from Operations: ₹278.69 lacs
  • Total Income: ₹283.83 lacs
  • Total Expenses: ₹507.12 lacs
  • Loss Before Tax: ₹(223.29) lacs
  • Tax Expense: ₹0.00 lacs
  • Net Loss for the Period: ₹(223.29) lacs
  • Basic & Diluted EPS: ₹(1.79)
  • Paid-up Equity Share Capital: ₹1247.00 lacs
  • Includes results of wholly-owned subsidiary Medgel Private Limited, which reported total income of ₹283.84 lacs and net loss after tax of ₹223.30 lacs.

Segment-wise Performance (Consolidated, Q1 FY27)

  • Pharma Division Revenue: ₹268.20 lacs; Segment Loss: ₹(164.33) lacs
  • Real Estate Division Revenue: ₹10.49 lacs; Segment Loss: ₹(58.96) lacs
  • Total Segment Loss: ₹(223.29) lacs

Dates of Action

  • Board Meeting Date: August 6, 2026 (commenced at 3:00 PM, concluded at 3:55 PM)
  • Effective date for Mrs. Saloni Garg's resignation from Senior Manager: August 6, 2026
  • Effective date for Mr. Akshit Garg's resignation from General Manager: August 6, 2026
  • Effective date for Mrs. Saloni Garg's appointment as Additional Director & Whole Time Woman Director: August 7, 2026, to August 6, 2029
  • Effective date for Mr. Alok K. Garg's reappointment as Chairman cum Managing Director: September 1, 2026, to August 31, 2029
  • Effective date for Mr. Akshit Garg's appointment as CFO & KMP: August 7, 2026
  • 43rd Annual General Meeting Date: September 22, 2026, at 12:30 PM IST

Parties Involved

  • Subsidiary: Medgel Private Limited (wholly-owned)
  • Statutory Auditors: Rawka & Associates (FRN: 021606C)
  • Individuals: Mrs. Saloni Garg (DIN: 11865402), Mr. Akshit Garg, Mr. Alok K. Garg (DIN: 00274321), Venus Rawka (Partner, Rawka & Associates)
  • Stock Exchange: BSE Limited

Purpose or Rationale

  • To comply with SEBI Listing Regulations (Regulation 30) by disclosing board meeting outcomes.
  • Management changes are due to internal appointments and resignations for new roles.

Financial or Operational Impact

  • The company reported net losses at both standalone and consolidated levels for Q1 FY27.
  • The real estate division generated ₹4.41 lacs from the sale of shops at Medi-caps Business Park.

Capital Structure Impact

  • No change in paid-up equity share capital reported (₹1247.00 lacs).

Forward-looking Guidance

  • No explicit forward-looking guidance or management commentary provided in the disclosure.

Notes

  • The financial results are unaudited but reviewed by the statutory auditors, Rawka & Associates.
  • Figures for previous periods have been re-stated/re-grouped/re-arranged/reclassified and/or recasted wherever necessary.
  • The results will be uploaded on the company's website (www.medicaps.com) and BSE website (www.bseindia.com).
  • A publication with a QR code and webpage details will be published in English and Hindi newspapers.